

Kateryna Stone, PhD*

Staff Scientist



T (617) 248-4004
kstone@choate.com

Practice Areas

Intellectual Property Protection

Education

University of Cincinnati
PhD (2024*) Pathobiology and Molecular
Medicine

University of South Florida
BS (2018) Cell and Molecular Biology

Kateryna Stone assists Choate's life sciences clients by utilizing her background in pathobiology, molecular medicine, and therapeutic ultrasound to help with the preparation and prosecution of patent applications, as well as freedom-to-operate and patentability analyses.

Industry Experience

Prior to joining Choate, Kateryna interned at Takeda with the Drug Metabolism and Pharmacokinetics team. There, she gained knowledge of the pharmaceutical industry in all phases of drug development, and worked to develop and validate 2 sensitive methods (flow cytometry and ELISA-based) to assess immunogenicity risk of therapies. Additionally, she worked on research projects involving lipid nanoparticle uptake, receptor occupancy for an antibody-drug conjugate, an imaging instrument optimization, and performed multi-parameter flow cytometry.

Kateryna worked as a graduate researcher at the University of Cincinnati, while pursuing her PhD in pathobiology and molecular medicine. Through her research and professional experience, she has in-depth experience with assay development and execution for a variety of translational therapies, including CRISPR-mediated gene editing, liquid nanoparticle generation, animal models of cancer / cardiovascular diseases, antibody characterization, biomarker validation, and oxygen scavenging.

Publications and Presentations

- "Assessing acoustic droplet vaporization efficiency and oxygen scavenging in whole blood", first author, *Ultrasound in Medicine in Biology*, in review
- "Impact of Perfluoropentane Microdroplets Diameter and Concentration on Acoustic Droplet Vaporization Transition Efficiency and Oxygen Scavenging", co-author, *Pharmaceutics*, November 2022
- "Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update", first author, *Cancers*, September 2021
- "A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma", co-author, *Frontiers of Oncology*, July 2021
- "mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors", co-author, *Journal of Thrombosis and Haemostasis*, January 2019